• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bausch + Lomb Corporation

    6/1/26 4:11:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    SD 1 formsd-2025blconflictminer.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    SPECIALIZED DISCLOSURE REPORT
    BAUSCH + LOMB CORPORATION
    (Exact name of the registrant as specified in its charter)
    Canada
    001-41380
    98-1613662
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (IRS Employer Identification No.)
    520 Applewood Crescent
    Vaughan, Ontario, Canada L4K 4B4
    (Address of principal executive offices)

    Alex Matheson
    Senior Vice President, Asst. General Counsel
    (908) 255-2864
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    X    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.












    Section 1 — Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    The Bausch + Lomb Corporation Conflict Minerals Report for the calendar year ended December 31, 2025 filed herewith as Exhibit 1.01, is available at www.bausch.com. The content of our website as referred to in this Form SD is included for general information only and is not incorporated by reference into this Form SD.
    Item 1.02 Exhibit
    The Conflict Minerals Report as required by Item 1.01 is filed as Exhibit 1.01 to this Form.
    Section 2 — Resource Extraction Issuer Disclosure
    Item 2.01 Resource Extraction Issuer Disclosure and Report
    Not applicable.
    Section 3 — Exhibits
    Item 3.01 Exhibits

    Exhibit Number    Description                                    
    1.01            Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    Bausch + Lomb Corporation
    (Registrant)
    /s/ A. Robert D. Bailey
    Date: June 1, 2026
    By (Signature and Title)
    (Date)
    A. Robert D. Bailey
    Executive Vice President, Chief Legal Officer


    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/28/26 5:10:51 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/28/26 5:09:41 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    5/28/26 5:07:59 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    SEC Form SD filed by Bausch + Lomb Corporation

    SD - Bausch & Lomb Corp (0001860742) (Filer)

    6/1/26 4:11:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by Bausch + Lomb Corporation

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    5/20/26 4:32:56 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by Bausch + Lomb Corporation

    10-Q - Bausch & Lomb Corp (0001860742) (Filer)

    4/29/26 4:36:44 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

    Blink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ Delivers clinically proven 3-in-1 extended relief,† providing instant, long-lasting dry eye symptom relief and locking in moisture Further strengthens Bausch + Lomb's position in the dry eye category Will be available at most retailers by the end of June 2026 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Triple Care Preservative Free eye drops, which provide instant, long-lasting reli

    6/1/26 6:59:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changi

    5/21/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the "Annual Meeting") held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Bernier 331,522,655 4,295,036 11,452,072 Steven H. Collis 331,575,559 4,242,132 11,452,072 Sarah B. Kavanagh 331,548,740

    5/20/26 4:49:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Ross Thomas W. Sr. bought $79,556 worth of shares (4,500 units at $17.68) and was granted 4,500 shares, increasing direct ownership by 15% to 69,391 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/4/26 4:18:54 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

    Revenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency1 Basis Compared to the First Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million Adjusted EBITDA (non-GAAP)1 of $189 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $200 Million Raising Full-Year 2026 Revenue and Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2026 financial results. "We're doing exactly what we said we would: driving sustainable growth and mar

    4/29/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, April 29, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53393 Participant Event Dial-in: +1 (888) 506-

    3/30/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations